Date of Activity
Date of Activity: 12 January 2012
Expires: 12 January 2013
The educational design and content of this website targets clinicians working in Europe in the field of endocrinology and diabetes, and those working in primary care or general practice with an interest in the management of patients with diabetes.
Statement of Need / Program Overview
Diabetes is an international epidemic; estimates suggest that in 2010 there were 55 million patients with diabetes in the European Union.
Despite the availability of multiple therapeutic options for the management of diabetes, surveys have shown that in clinical practice, target levels of HbA1C are often not achieved. This may be related to clinicians’ and other healthcare providers’ fears of provoking adverse events, particularly hypoglycaemia and weight gain. In addition, these adverse events can lead to poor patient compliance, and it is important that the clinician is able to select from different classes of antidiabetes therapy and combine them appropriately for an individual patient.
An important new approach, which is nearing clinical reality, is to target glucose reabsorption in the kidney through inhibition of SGLT2. Now that clinical data are becoming available, Strategic Consultants International, and Global Education Group have identified an educational need to provide information on this important new mechanism of action. By providing an insight into the mechanistic rationale and the clinical evidence to date for this new class, healthcare providers are able to consider the possible benefits and tolerability profile in order that they can consider the potential role of these agents in future clinical practice.
This activity comprises a single presentation, offered in 5 languages (English, Spanish, Italian, German and French) as a video capture. A monograph of the activity content is also available to download.
The presentation discusses the following:-
- Burden and impact of diabetes
- Current standards of care and unmet needs
- SGLT2 inhibition: Rationale
- SGLT2 inhibition: Clinical results to-date
- Considerations for the clinic: How, where and in which patients might these novel agents have a role
At the conclusion of this activity, participants should be better able to:
- State the rationale for targeting glucose reabsorption by the kidney in patients with diabetes
- Describe current glycaemic control of type 2 diabetes and current unmet needs
- Evaluate the evidence for SGLT2 inhibitors as therapy of type 2 diabetes
- Identify how SGLT2 inhibitors might be incorporated into clinical practice
John Wilding DM, FRCP
Professor of Medicine
The Faculty of Medicine
Senior Lecturer in Medicine
Honorary Consultant Physician
Diabetes & Endocrinology Unit
University of Liverpool
Santiago Duran-Garcia, MD, PhD
Professor of Endocrinology and Nutrition
Hospital Universiatario de Valme,
Bernard Charbonnel, MD
Professor of Endocrinology and
University of Nantes
Head of Internal Medicine,
Endocrinology and Diabetes,
Ele Ferrannini, MD
Professor of Internal Medicine
University of Pisa School of Medicine
Chief of the Metabolism Unit of the
National Research Council
Michael Stumvoll, MD
Professor of Medicine
Head of Division of Endocrinology,
Diabetes and Nephrology
University of Leipzig
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Global Education Group (Global) and Strategic Consultants International. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Accreditation Council for Continuing Medical Education (EACCME) and the American Medical Association (AMA) signed an agreement of mutual recognition of CME credits between Europe and the USA whereby European physicians have their US credits recognized in Europe.
This educational activity has been approved by the Royal College of Physicians for 1 CPD credit (RCP event code 73473).
This educational activity has been approved by the Italian Ministry of Health for 1.0 Credits.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the activity, then download and complete the evaluation and credit request. The post-test, evaluation, and application for credit must be returned to Global. You may fax them to 001 303 648-5311 or email them to firstname.lastname@example.org.
Disclosure of Conflicts of Interest
Global Education Group requires instructors, planners, managers and other individuals and their spouse / life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse / life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|John Wilding, DM, FRCP||Consultant/Independent Contractor: Astellas, BMS/AstraZeneca, Johnson & Johnson, NovoNordisk, Prosidion
Speaker’s Bureau: BMS/Astrazeneca, Merck, Novo Nordisk
|Santiago Duran-Garcia, MD, PhD||Nothing to disclose|
|Ele Ferrannini, MD||Consultant/Independent Contractor: Astellas, BMS/AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Lilly, MSD, Sanofi
Grant/Research Support: Amylin, Boehringer Ingelheim, Lilly
Honoraria: Astellas, BMS/AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Lilly, MSD, Sanofi
|Bernard Charbonnel, MD||Consultant/Independent Contractor:
AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Novartis, Novo Nordisk, Merck Sharpe & Dohme, Sanofi-Aventis, Roche,Takeda.
Honoraria: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Novartis, Novo Nordisk, Merck Sharpe & Dohme, Sanofi-Aventis, Roche,Takeda
Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Novartis, Novo Nordisk, Merck Sharpe & Dohme, Sanofi-Aventis, Roche,Takeda
|Michael Stumvoll, MD||Grant Research Support: Lilly
Honoraria: BMS, Novartis and Sanofi
|Name of Planner or Manager||Reported Financial Relationship|
|Jackie Dawson, MSN||Nothing to disclose|
|Amanda Glazar, PhD||Nothing to disclose|
|Hilary Eadon||Nothing to disclose|
|Ian Morgan||Nothing to disclose|
|*Required to view printable (PDF) version of the lesson.|
|Microsoft Windows 2000 SE or above.
Flash Player Plugin (v188.8.131.52 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
|MAC OS 10.2.8
Flash Player Plugin (v184.108.40.206 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.
There is no fee for this educational activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and / or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Strategic Consultants International do not recommend the use of any agent outside of the labelled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.